November 22, 2019
Mad Hedge Technology Letter November 22, 2019 Fiat Lux Featured Trade: (THE REAL STORY BEHIND THE CHARLES SCHWAB/TD AMERITRADE MERGER), (SCHW), (AMTD), (ETFC), (IBKR)
This author has not written his bio yet.
But we are proud to say that Mad Hedge Fund Trader contributed 13681 entries already.
Mad Hedge Technology Letter November 22, 2019 Fiat Lux Featured Trade: (THE REAL STORY BEHIND THE CHARLES SCHWAB/TD AMERITRADE MERGER), (SCHW), (AMTD), (ETFC), (IBKR)
There are certain parts of tech that I routinely bash on like travel tech, music streaming tech, and the usefulness of social media companies. One other group of companies that I’m just as sour on are the discount e-brokers. Yes, tech has embedded deflation into every company causing operations to become more efficient while boosting
“I am so disturbed by kids who spend all day playing videogames.” – Said Co-Founder and CEO of Oracle Larry Ellison
Global Market Comments November 22, 2019 Fiat Lux Featured Trade: (TRADING THE KENNEDY ASSASSINATION)
While the Diary of a Mad Hedge Fund Trader focuses on investment over a one week to a six-month time frame, Mad Day Trader, provided by Bill Davis, will exploit money-making opportunities over a brief ten minute to three-day window. It is ideally suited for day traders, but can also be used by long-term investors to improve market timing for entry and exit points.
Global Market Comments November 21, 2019 Fiat Lux SPECIAL TESLA ISSUE Featured Trade: (TESLA TALES), (TSLA)
When a guest asked me to name a clear ten bagger stock for the coming decade at the Mad Hedge Technology Letter, I didn’t hesitate. It was Tesla (TSLA). At long last, investors are perking up and taking notice of the Fremont, California based electric car manufacturer whose shares have been trapped in a highly
Mad Hedge Biotech & Healthcare Letter November 21, 2019 Fiat Lux Featured Trade: (WHY VERTEX HAS BEEN ON FIRE), (VRTX), (CRSP)
Vertex Pharmaceuticals Inc. (VRTX) is the unequivocal king of the genetically rare lung condition cystic fibrosis (CF). To further prove its stronghold of the market, the company recently received FDA approval for its fourth CF treatment called Trikafta — five full months ahead of schedule and merely three months following the company’s application. In a
“Humans are vastly underestimated,” said Tesla founder Elon Musk.
Legal Disclaimer
There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.
